MDC Holdings Inc Files For Mixed Shelf Of Up To $5B

-Reutrs

-Reutrs

Total
0
Shares
Related Posts
Read More

Verrica Pharmaceuticals Announces Presentation Of Lesion Clearance Data From An Ongoing Phase 2 Study Of VP-315 For The Treatment Of Basal Cell Carcinoma At The American Academy Of Dermatology 2023 Innovation Academy Meeting

Presentation highlights the antitumor response of VP-315 for the non-surgical treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance   There are approximately 3-4

VRCA